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Abstract
Objective—Despite its large clinical impact, the underlying mechanisms for vein graft failure 
remain obscure and no effective therapeutic solutions are available. We tested the hypothesis that 
Notch signaling promotes vein graft disease.
Approach and Results—We used two biotherapeutics for Delta-like ligand 4 (Dll4), a Notch 
ligand: 1) blocking antibody; and 2) macrophage- or endothelial cell (EC)-targeted small-
interfering RNA (siRNA). Dll4 antibody administration for 28 days inhibited vein graft lesion 
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development in LDL-receptor deficient (Ldlr−/−) mice, and suppressed macrophage accumulation 
and macrophage expression of pro-inflammatory M1 genes. Dll4 antibody treatment for 7 days 
after grafting also reduced macrophage burden at Day 28. Dll4 silencing via macrophage-targeted 
lipid nanoparticles reduced lesion development and macrophage accumulation, while EC-targeted 
Dll4 siRNA produced no effects. Gain-of-function and loss-of-function studies suggested in vitro 
that Dll4 induces pro-inflammatory molecules in macrophages. Macrophage Dll4 also stimulated 
smooth muscle cell (SMC) proliferation and migration and suppressed their differentiation.
Conclusion—These results suggest that macrophage Dll4 promotes lesion development in vein 
grafts via macrophage activation and crosstalk between macrophages and SMC, supporting the 
Dll4-Notch axis as a novel therapeutic target.
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Introduction
Vein graft failure is a global health burden with no effective medical solutions.1 Due to the 
pandemic of atherosclerotic peripheral artery disease (PAD) and the growing prevalence of 
underlying metabolic disorders,2 the incidence of vein graft failure is rising. Although many 
mechanisms for arterial diseases have been established, the pathogenesis of vein graft failure 
remains incompletely understood. Autologous saphenous vein grafts (SVG) are widely used 
for PAD because they remain patent longer than artificial conduits.3 Approximately 50% of 
lower extremity SVG, however, become occluded or narrowed within a year.4 When PAD 
grafts fail, the only available therapeutic options are devastating limb amputation or invasive 
and expensive angioplasty or surgical revascularization. Coronary artery SVG also fail at 
high rates.5 Although current therapies such as statins can reduce the onset of complications 
of arterial diseases (e.g., myocardial infarction),6 no effective medical solutions are available 
for vein graft failure.
The Notch pathway, involving ligands (Delta-like ligand 1 [Dll1], Dll3, Dll4, Jagged1, 
Jagged2) and receptors (Notch1-4), contributes to biological processes during development 
and to disease mechanisms in adults.7, 8 Direct cell-to-cell contract via the binding of a 
ligand to a Notch receptor, both of which are expressed on the cell surface, triggers 
downstream responses.9 We previously demonstrated that Dll4-mediated Notch signaling 
promotes macrophage activation.10, 11 Clinical and preclinical evidence has established the 
causal role of macrophages in arterial atherosclerosis.12, 13 Failing vein grafts also tend to 
contain macrophages,2, 14 but their role in the disease progression remains unclear. To test 
the hypothesis that macrophage Notch signaling contributes to the pathogenesis of vein graft 
disease, the present study used two clinically-relevant biotherapeutics: 1) Dll4 blocking 
antibody; and 2) Dll4 siRNA encapsulated in macrophage- or endothelial cell (EC)-targeted 
lipid nanoparticles (LNP).
Materials and Methods
Materials and Methods are available in the online-only Data Supplement.
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Results
Increased expression of Dll4 in macrophages in human and mouse vein grafts
In control human saphenous veins before grafting, little if any intimal cells were 
immunoreactive for Dll4, whereas the thickened intima of failed human SVG contained 
many cells expressing Dll4 (Figures 1A; Supplemental Figure I). In the failed grafts, some 
CD68-positive intimal macrophages were immunoreactive to Dll4 antibody (Supplemental 
Figure IB). In high-cholesterol/high-fat-fed Ldlr−/− mice, IVC implanted into the carotid 
artery developed more advanced lesions than in wild-type mice.15 The neointima of vein 
grafts in Ldlr−/− mice showed features similar to those of advanced arterial plaques prone to 
rupture, including foam cell accumulation, microvessels, and intraplaque hemorrhage 
(Supplemental Figure II), supporting previous reports on a similar model in 
hypercholesterolemic ApoE3*Leiden mice by the Paul Quax group.16, 17 Vein grafts of Ldlr
−/− mice expressed higher levels of Dll4 mRNA compared to native IVC of Ldlr−/− or wild-
type mice (qPCR, Figure 1B). In mouse vein grafts, Dll4 localized primarily to intimal 
macrophages, while smooth muscle cell (SMC) expression of Dll4 was minimal (Day 28, 
double immunofluorescence, Figure 1C). Ligand binding promotes the cleavage of Notch 
receptors and release of the intracellular domain.9 The amount of Notch1 intracellular 
domain (NICD), as identified by the antibody that recognizes the neoepitope, thus indicates 
the levels of Notch signaling activation. NICD accumulated primarily in intimal 
macrophages of vein grafts 28 days after implantation, while few if any smooth SMC and 
EC were stained positively (Supplemental Figure III). Dll4 and NICD were almost 
undetectable in the native IVC (Supplemental Figure IVA). But the amounts of 
immunoreactive Dll4 and NICD in the intima of mouse vein grafts increased in parallel over 
time (Supplemental Figures IVA and IVB), indicating acceleration of Notch signaling 
activation during the lesion development. Furthermore, the amounts of Dll4 and NICD 
correlated positively with the wall area (Supplemental Figure IVC). These results suggest 
that Dll4-Notch signaling is accelerated during the development of vein graft lesions.
Blockade of Dll4 reduces lesion formation and inflammation in vein grafts
Blocking antibody for Dll411, 18, 19 was administered to Ldlr−/− mice twice a week for 28 
days. Reduced amounts of NICD following antibody administration indicate that Dll4 
mediates Notch activation in vein graft lesions (Figure 1D). Dll4 blockade produced no 
effects on serum levels of total cholesterol (801.0 ± 51.5 vs. 867.0 ± 15.7 mg/dL), 
triglycerides (216.2 ± 19.3 vs. 249.3 ± 36.1 mg/dL), and body weight (29.6 ± 0.7 vs. 30.5 
± 1.1 g). We previously verified that administration of the same antibody for 3 months did 
not affect blood pressure, food consumption, and physical activity in Ldlr−/− mice.11
Histologic assessment demonstrates that 28 days of Dll4 antibody treatment decreased the 
area and thickeness of the intima of vein grafts in Ldlr−/− mice but produced no significant 
changes in the lumen diameter, media/adventitia thickness, or vessel diameter (Figure 2A). 
Noninvasive ultrasonography is routinely used to monitor the patency of vein grafts in 
patients. Clinically relevant ultrasound imaging visualized and quantified the decreased wall 
area and volume of vein grafts, but no significant changes in the lumen area, in mice treated 
with Dll4 antibody (Figures 2B and 2C), which is consistent with the microscopic data. 
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Dll4 blockade also reduced the accumulation of macrophages (Mac3-positive cells), SMC 
(α–SMA), and proliferating cells (PCNA) in the intima (Figure 2D). Proliferation of 
macrophages and SMC may contribute to the pathogenesis of vascular diseases.20-23 
Blockade of Dll4 reduced proliferating macrophages and SMC, as demonstrated by double 
immunofluorescence with PCNA (Supplemental Figure V). Inflammation in the adventitia 
may contribute to the pathogenesis of vascular diseases.24 Dll4 antibody therapy, however, 
did not reduce adventitial macrophages significantly (Supplemental Figure VI).
To examine whether Dll4 plays a major pathological role in the early processes of venous 
responses to the arterial environment and ask a more clinical question whether a shorter 
antibody administration after surgery is also effective, we administered Dll4 antibody only 
for 7 days after graft implantation. This one-week Dll4 blockade did not reduce lesion size 
at Day 28 (Supplemental Figure VIIA). It should be noted, however, that this short 
treatment produced a statistically significant reduction of intimal macrophage accumulation, 
which was sustained until 21 days later (Day 28) without continued antibody administration 
(Supplemental Figure VIIB). We previously reported that Dll4 blockade for 12 weeks 
improves glucose tolerance and insulin sensitivity.11 As demonstrated in the present study, 
Dll4 blockade for 7 or 28 days significantly reduced macrophage accumulation in vein 
grafts. To address whether improved glucose metabolism may have contributed to the 
beneficial effects of Dll4 suppression on vein grafts, we examined glucose tolerance and 
insulin sensitivity 7 days after the initiation of antibody administration. Seven-day Dll4 
antibody treatment caused no effects on these metabolic parameters (Supplemental Figure 
VIII).
We further examined the effects of Dll4 suppression on the inflammatory burden in vein 
grafts. Dll4 antibody-treated vein grafts contained lower levels of IL-1β, TNF-α, and PDGF-
B mRNA compared to control grafts (Figure 3A). To examine whether the reduced 
expression of these factors merely resulted from diminished macrophage number, or whether 
Dll4 blockade also reduced macrophage activation, we performed qPCR on macrophages 
isolated from vein grafts. Dll4 antibody treatment decreased macrophage expression of 
IL-1β and TNF-α, molecules typical of a pro-inflammatory “M1” phenotype (Figure 3B).13 
In contrast, Dll4 antibody therapy increased arginase 1 that represents non/anti-
inflammatory “M2” polarization (Figure 3B). A reduction of Hey2, a prototypical Notch 
target gene, indicates that Dll4 antibody indeed suppressed Notch signaling in macrophages. 
These results indicate that Dll4 suppression diminishes the pro-inflammatory 
microenvironment in vein grafts.
Dll4 blockade suppresses MMP activity and reduces thin collagen fibers
In vivo molecular imaging further assessed the effects of Dll4 suppression on macrophage 
activation in vein grafts. We co-injected two imaging agents that elaborate near-infrared 
signals to visualize macrophage phagocytic activity (AminoSPARK, 750 nm) and MMP 
activity (MMPSense, 680 nm). Dll4 blockade inhibited macrophage phagocytic activity and 
MMP activity in parallel (Figure 4A). Notably, Dll4 antibody therapy reduced macrophage 
activation in vein grafts as early as 7 days after implantation, supporting our microscopic 
observation (Supplemental Figure VII). MMP produced by activated macrophages impair 
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collagen content and structures.12, 22 Picrosirius red staining viewed under a circularly 
polarized microscope showed no significant difference in the content of total fibrillar 
collagen between two groups (Figure 4B). Collagen hue analysis, however, revealed that 
Dll4 blockade decreased thin collagen fiber (Figure 4B), indicating that collagen 
degradation by macrophage-derived proteolytic activity may have reduced.
Macrophage-targeted Dll4 silencing inhibits intimal thickening and macrophage 
accumulation
To determine the relative contribution of macrophage Dll4 to the development of vein graft 
lesions, we used macrophage-targeted LNP (C12-200) to deliver Dll4 siRNA in vivo.25, 26 In 
pilot experiments, a single injection of 0.5 mg/kg C12-200-siDll4 resulted in a 51% 
reduction of Dll4 mRNA in splenic macrophages in 72 hours (Figure 5A). To validate the 
selectivity of Dll4 silencing to macrophages in vivo, we administered 0.5 mg/kg C12-200-
siDll4 at 21 days and 24 days after vein graft implantation. qPCR of intimal tissues 
containing endothelium or macrophage clusters isolated by laser capture microdissection 
showed inhibition of Dll4 expression in vein graft macrophages by > 70%, but no effect in 
endothelium (Figure 5B).
C12-200-siDll4 was then injected at 0.5 mg/kg, twice a week, in Ldlr−/− mice. C12-200-
siDll4 decreased intimal area and thickness as compared with control C12-200 containing 
non-targeting siRNA (Figure 5C). C12-200-siDll4 reduced macrophage accumulation in the 
intimal layer (Figure 5D), although it did not significantly increase thick collagen fibers 
(Figure 5E). These results indicate that Dll4 expressed by macrophages contributes to the 
lesion formation and macrophage burden in vein grafts.
Dll4 regulates expression of pro-inflammatory molecules in macrophages
To explore mechanistic evidence for the causal role of Dll4 in macrophage activation, we 
performed gain-of-function and loss-of-function experiments in mouse primary 
macrophages. Transient overexpression of Dll4 induced prototypical Notch target genes 
Hes1 and Hey1 (Figure 6A). Enforced expression of Dll4 induced pro-inflammatory 
molecules typical of “M1” macrophages (e.g., IL-1β, TNF-α; Figure 6B). In contrast, Dll4 
blocking antibody exerted opposing effects (Figure 6C). Furthermore, Dll4 blockade 
inhibited the expression of pro-inflammatory genes iNOS and TNF-α induced by IFN-γ, a 
typical “M1” stimulation (Figure 6D). These in vitro findings are consistent with in vivo 
data shown in Figure 3.
Macrophage Dll4 promotes SMC migration, proliferation, and de-differentiation
SMC migration and proliferation may contribute to the development of vein graft lesions.21 
Notch signaling requires the direct cell-cell contact via the ligand-receptor binding. SMCs in 
the intima of atherosclerotic plaques and vein grafts are, however, surrounded by 
extracellular matrix and generally lack membrane contacts with neighboring SMCs, while 
such direct contacts are common in plaque macrophages,14, 27, 28 suggesting that direct 
physical interactions between SMC and macrophages via Dll4-Notch binding may hardly 
occur. Nevertheless, we examined the effects of Dll4 binding to SMC in vitro using primary 
human saphenous vein SMC (HSVSMC). Immobilized recombinant Dll4 (rDll4) attachment 
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did not affect the number of HSVSMCs both in 0.5% and 10% FBS (Supplemental Figure 
IXA). Blockade of Dll4 binding also produced no effects on the growth of HSVSMC 
(Supplemental Figure IXB). These results indicate that direct Dll4 binding may not play a 
major role in SMC biology. Therefore, we performed indirect co-culture experiments to 
examine whether macrophage expression of Dll4 induces SMC migration, proliferation, and 
de-differentiation by soluble factors in a paracrine fashion. Conditioned media from 
RAW264.7 cells transfected with Dll4 plasmid accelerated SMC migration (Figure 7A), 
increased SMC number (Figure 7B), and suppressed their expression of myosin heavy chain 
(SM-MHC), the strictest SMC differentiation marker (Figure 7C).29 PDGF-BB induces 
SMC migration, proliferation, and de-differentiation.30, 31 Notch activation by enforced 
expression of Dll4 or immobilized rDll4 induced PDGF-B expression in RAW264.7 cells 
(Figures 7D and 7E), indicating that PDGF-BB may mediate the effects of Dll4 via 
macrophage–SMC crosstalk. Other pro-inflammatory factors, which Dll4 induces in 
macrophages, may contribute this interaction (Figure 6).
The role of EC-derived Dll4 in the development of vein graft lesions
Among human primary macrophages, HSVSMC, and human saphenous vein EC (HSVEC), 
Dll4 mRNA levels were highest in HSVEC under the quiescent state (Supplemental Figure 
XA). LPS markedly induced Dll4 only in primary macrophages (Supplemental Figure 
XA). Endothelium also appeared positive for Dll4 in the failed human vein grafts 
(Supplemental Figure I). In HSVEC, blockade of Dll4 suppressed MCP-1, IL-1β, IL-6, 
and VCAM-1 expression (Supplemental Figure XB). In contrast, immobilized Dll4 
induced EC expression of IL-1β and VCAM-1 (Supplemental Figure XC). Dll4 antibody 
treatment reduced the number of adventitial microvessels (Supplemental Figure XI). We 
therefore explored a new mechanism by which EC-derived Dll4 participates in the 
pathogenesis of vein graft disease using Dll4 siRNA formulated in EC-targeted LNP 7C1 
(7C1-Dll4 siRNA).32 Dll4 by 7C1-Dll4 siRNA reduced Dll4 mRNA in endothelium by > 
70% (Figure 8A). Despite the high silencing efficacy, EC-targeted Dll4 suppression 
produced no effects on several parameters for the development of vein graft lesions (intima 
area, intima thickness, lumen diameter, media/intima thickness, and vessel diameter; 
Figures 8B and 8C). These results further support a major role for macrophage Dll4 in vein 
graft disease.
Discussion
Although many mechanisms have been proposed and validated for arterial diseases, the 
pathogenesis of vein graft disease remains obscure. Using two different biotherapies — 
blocking antibody and macrophage-targeted siRNA, the present study demonstrates novel 
mechanisms by which macrophage Dll4 promotes the development of vein graft lesions. 
Accumulating evidence has established that macrophages contribute to various mechanisms 
for arterial diseases, including plaque rupture.6, 12, 13 The role of macrophages in vein graft 
disease, however, remains elusive. Failing vein grafts in patients exhibit macrophage 
accumulation14 and signs of rupture.33, 34 Clinical evidence has linked biomarkers of 
inflammation with vein graft failure.35 Preclinical studies proposed the role of macrophages 
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in neointima formation in vein grafts.16, 36, 37 However, no medical therapies are currently 
available to target vein graft inflammation, which has driven our current efforts.
The key novel findings demonstrated in the present study include: 1) the expression of Dll4 
by macrophages in the intima of human and mouse vein grafts; 2) increased Dll4 expression 
and NICD accumulation during the development of experimental vein graft lesions; 3) 
positive correlations between the graft wall area and Dll4 expression or NICD accumulation; 
4) reduced vein graft lesions after Dll4-targeted biotherapeutics (blocking antibody and 
macrophage-selective Dll4 siRNA); 5) the role of Dll4-Notch signaling in macrophage and 
SMC growth in vein grafts; 6) the effects of Dll4 blockade on macrophages being 
independent of metabolic effects; 7) the potential role of Dll4 in EC activation; 8) no 
substantial in vivo role for EC-derived Dll4 in vein graft disease as demonstrated by EC-
targeted Dll4 siRNA; and 9) the role of Dll4-expressing macrophages in SMC de-
differentiation, migration, and proliferation via a paracrine mechanism.
The previous studies including our own suggested that Notch signaling components, 
including Dll4, contribute to various biologies of hematopoietic cells.10, 11, 38-43 However, 
the mechanistic evidence for the role of Dll4 in inflammation of cardiovascular organs 
remains scant.10, 11 Macrophage polarization, as often classified by at least two 
subpopulations: a pro-inflammatory (“M1”) and an anti/non-inflammatory (“M2”), is 
associated with various cardiovascular diseases.13, 44 In vein grafts, Dll4 blockade reduced 
the expression of multifunctional pro-inflammatory IL-1β and TNF-α, typical “M1” 
molecules, suggesting the broad anti-atherogenic effects of Dll4 antibody via suppression of 
a positive feedback loop of sustained macrophage activation and providing insight into the 
clinical impact of this therapy. Examining the relative contribution of macrophage-derived 
Dll4 used the macrophage-targeted LNP C12-200. Dll4 silencing in macrophages via 
C12-200 decreased intimal thickening and macrophage burden.
Our in vitro evidence in the present study suggests a role for Dll4 in EC activation. 
Therefore, we used EC-targeted LNP 7C1 to explore an additional potential mechanism for 
vein graft disease mediated by EC-derived Dll4. Despite an excellent silencing efficacy in 
endothelium, Dll4 siRNA formulated in 7C1 produced no effects on the development of vein 
graft lesions, as quantitatively determined by several parameters. These results provide 
another line of evidence for the pivotal role of Dll4 expressed by macrophages in the 
development of inflamed vein grafts.
Phenotypic modulation of SMC contributes to the pathogenesis of arterial diseases.29 SMC 
activation may also participate in the pathogenesis of vein graft disease.21 The present study 
therefore explored the novel mechanism that Dll4 in SMC promotes activation of this 
vascular cell type. Dll4 expression levels were, however, much lower in quiescent or 
activated primary human SMC than those in macrophages or EC. Dll4 binding to primary 
SMC did not induce their proliferation. In addition, previous studies demonstrated a lack of 
membrane contact between SMC surrounded by extracellular matrix, while direct contact 
between macrophages is common.27, 28 Notch signaling activation requires direct cell-to-cell 
contact that allows ligand-receptor binding. Thus, Dll4-Notch interaction between 
neighboring SMC or between SMC and macrophages may not occur so frequently in 
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vascular lesions. Instead, a series of experiments reported in the present study suggest a 
novel paracrine mechanism by which macrophage Dll4 activates neighboring SMC 
(Supplemental Figure XIIA).
To maximize clinical significance of our study, we used two scientifically validated and 
clinically relevant techniques to suppress Dll4 — RNAi mediated by LNP and antibody 
administration. The gene silencing by siRNA oligos formulated in LNP, a robust and well-
established research tool for investigating the role of macrophage gene expression in vivo, 
enabled us to selectively target Dll4 in macrophages or EC, as documented in the previous 
studies.25, 26, 32, 45, 46 It should be noted that the delivery of siRNA in such LNP has already 
been used in humans and proven safe and effective, contributing to the generation of 
promising clinical data.47-49 In addition, antibody therapies for chronic diseases have 
become widely available in the clinic. For instance, a Phase IIb clinical trial on 4 months of 
anti-IL-1β monoclonal antibody treatment presented anti-inflammatory effects (e.g., 
reductions in C-reactive protein levels) with no substantial adverse effects,50 leading to a 
longer, larger cardiovascular outcome study. In the present study, Dll4 antibody therapy for 
only 7 days exerted beneficial effects on lesional macrophages in vein grafts. The use of 
such clinically relevant therapeutics suggests how our preclinical findings could be 
translated into the clinical development of Dll4-targeted therapies for vein grafts. In 
addition, noninvasive ultrasonography of vein grafts, a routine procedure in the clinic, in live 
mice supports the microscopic findings. These lines of evidence indicate the clinical 
translatability of our mouse study.
In conclusion, we provides the novel evidence that the Dll4-Notch axis contributes to the 
pathogenesis of vein graft lesion development (Supplemental Figure XIIA). 
Complementary in vivo experiments using macrophage- or EC-targeted siRNA demonstrate 
the relative contribution of macrophages to the development of vein graft lesions mediated 
by Dll4. The study has identified Dll4 as a new promising therapeutic target for vein graft 
failure (Supplemental Figure XIIB), a major clinical problem with no medical solutions.
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Translational Perspective
Although vein graft failure is a major clinical problem, no medical therapies are 
available. Using clinically relevant biotherapies — blocking antibody and siRNA-loaded 
nanoparticles, we demonstrate Dll4 promotes inflammation and lesion development in 
mouse vein grafts, providing novel mechanisms and new therapeutic solutions for this 
disease.
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Figure 1. Dll4 expression increases in human and mouse vein grafts
(A) Human SVG harvested for bypass surgery (control native vein, left) and failed SVG 
(right). Sections were stained with anti-Dll4 antibody. Scale bar indicates 300 μm. L, lumen; 
A, adventitia. Similar data on additional samples (4 control veins; 4 failed SVG) are shown 
in Supplemental Figure I. (B) Dll4 mRNA in mouse vein grafts (VG) analyzed 28 days after 
grafting. Data are shown as relative expression normalized by native IVCs from wild type 
(WT) mice. n = 5 to 8. (C) Serial section of mouse vein graft stained with anti-Dll4, anti-
Mac-3, and anti-α–SMA antibodies. Arrowheads indicate cells positive for both Mac3 and 
Dll4. Scale bar indicates 200 μm. The data represent 5 mice that showed similar results. (D) 
Immunostaining of cleaved Notch1 intracellular domain (NICD) at 28 days after vein 
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grafting. Scale bars indicate 100 μm. Bar graph shows quantification of Notch signal 
activation evaluated as a percentage NICD-positive area in intima. n = 4.
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Figure 2. Antibody blockade of Dll4 for 28 days inhibits lesion formation in vein grafts
(A) Vein graft harvested 28 days after implantation from control IgG or Dll4 antibody-
treated animals and results of morphometric analyses. Scale bar indicates 400 μm. n = 10 
and 9. (B) Ultrasonographic images of vein grafts treated with control IgG (left) and anti-
Dll4 antibody (right) 28 days after implantation. The white dotted line indicates vessel wall 
area. (C) Lumen and vessel wall area (mm2), and vessel wall volume (mm3) of 
ultrasonographic images in control IgG or Dll4 antibody treated vein grafts (n=5 and 3). (D) 
Immunostaining of Mac-3, α–SMA, and PCNA at day 28 and quantitative data shown as 
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percentages of staining positive area (Mac-3, α–SMA) and PCNA positive nucleus in the 
intima. Scale bar indicates 200 μm. n = 4 to 7.
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Figure 3. Antibody blockade of Dll4 for 28 days inhibits the expression of pro-inflammatory 
molecules in vein grafts and lesional macrophages
mRNA expression of molecules associated with inflammation, macrophage phenotype, 
matrix degradation, and thrombogenicity were quantified in vein grafts (C) and F4/80 
positive macrophages isolated from vein grafts (D) 7 days after graft implantation. Data are 
represented as fold change by Dll4 antibody relative to control IgG. PAI-1, plasminogen 
activator inhibitor-1; TF, tissue factor; CCR2, C-C chemokine receptor type 2. n = 3 to 7.
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Figure 4. Blockade of Dll4 attenuates macrophage activation and collagen thinning
(A) Live molecular imaging of macrophage functions. Fluorescent probes (AminoSPARK 
750 for phagocytic activity and MMPSense 680 for MMP activity) were co-injected 24 
hours before intravital microscopy. Dll4 antibody therapy reduced macrophage MMP 
activity in vein grafts as early as 7 days after implantation. n = 4 to 11.. (B) Collagen content 
in the intima of vein grafts was quantified by picrosirius red staining under a polarized 
microscopy. Photomicrographs demonstrate representative samples without (top) or with 
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(bottom) polarized light. Circle graphs indicate a ratio of green (thin) vs. red (thick) collagen 
fibers. n = 6 and 5.
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Figure 5. The relative contribution of macrophage Dll4 in vein graft lesion development as 
examined via siRNA delivery to macrophages
(A) Macrophage-targeted LNP containing control siRNA (Ctrl) or Dll4 siRNA (siDll4) were 
injected via tail vein, and F4/80 positive splenic macrophages were isolated. Dll4 mRNA 
was quantified by real-time PCR. n = 7. (B) Dll4 mRNA was quantified by real-time PCR in 
macrophages (Mϕ) or endothelial cells (EC) collected by laser capture microdissection. n = 
5-6 sections. (C) Masson-Trichrome staining of vein grafts at day 28. Scale bars indicate 400 
μm. n = 9 and 8. (D) Mac-3 immunostaining at day 28. n = 6. Scale bars indicate 200 μm. 
(E) Collagen analysis. Collagen content was analyzed 28 days after vein grafting by 
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picrosirius red staining under a polarized microscope. Collagen hue analysis measured thin 
(green) and thick (red) collagen fibers. n = 6 and 8.
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Figure 6. In vitro gain-of-function and loss-of-function studies in primary macrophages
(A and B) A gain-of-function study. Immunofluorescence image of peritoneal macrophages 
24 hours after control plasmid (Control-P) or Dll4 plasmid (Dll4-P) transfection (A). Bar 
graph shows quantitative analyses of Dll4 and prototypical Notch target genes (n = 3, B) 
Data are represented as fold change by Dll4 plasmid transfection relative to control plasmid 
transfection. n = 6. (C) A loss-of-function study. Data are represented as fold change by Dll4 
blocking antibody relative to control IgG. n = 5 and 6. (D) mRNA expression after IFN-γ 
stimulation. Peritoneal macrophages were incubated overnight with control IgG or Dll4 
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antibody, and then stimulated with 10 ng/mL IFN-γ for 4 hours. Bar graphs show results of 
real-time PCR. n = 4.
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Figure 7. Macrophage–SMC crosstalk as a possible mechanism of vein graft lesion development
(A) SMC migration was examined by modified Boyden's chamber method. DMEM, control 
Dulbecco's modified Eagle's medium; RAW-CM, conditioned media from non-treated 
RAW264.7 cells; Control-CM, CM from control plasmid transfected RAW264.7 cells; Dll4-
CM, CM from Dll4 plasmid transfected RAW264.7 cells. n = 4. (B) SMC proliferation 
induced by RAW-CM. RAW-CM increased SMC number compared with DMEM (above). 
Dll4-CM augmented CM-induced SMC growth (below). FBS; fetal bovine serum. n = 8. (C) 
mRNA level of SMC differentiation markers after 24 hours of incubation with CM. Data are 
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shown as relative expression normalized by SMC treated with Control-CM. n = 6. (D) 
mRNA expression levels of PDGF-B 24 hours after Dll4 plasmid transfection or 
immobilized Dll4 stimulation. Control-P, control plasmid; Dll4-P, Dll4 plasmid. n = 6 (left) 
and n = 7-8 (right). (E) Western blot of PDGF-B. Protein was extracted 24 hours after 
plasmid transfection.
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Figure 8. The relative contribution of endothelial cell (EC)-derived Dll4 in vein graft lesion 
development as examined via siRNA delivery to endothelium
EC-targeted lipid nanoparticles (7C1) containing control siRNA (Ctrl) or Dll4 siRNA 
(siRNA) were injected via tail vein. (A) Dll4 mRNA levels were quantified by real-time 
PCR in the endothelium isolated by laser capture microdissection. (B) Masson-Trichrome 
staining of vein grafts at day 28. Scale bars indicate 500 μm. (C) Bar graphs demonstrate the 
results of quantitative morphometric analysis (each n=6).
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